QGEN:NGS-Qiagen N.V. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 41.65

Change

0.00 (0.00)%

Market Cap

USD 6.46B

Volume

1.41M

Analyst Target

USD 52.64
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Qiagen NV provides sample and assay technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
TMO Thermo Fisher Scientific Inc

-2.33 (-0.39%)

USD 218.67B
DHR Danaher Corporation

-1.77 (-0.70%)

USD 186.23B
A Agilent Technologies Inc

-2.00 (-1.34%)

USD 43.89B
IQV IQVIA Holdings Inc

-5.04 (-2.15%)

USD 42.75B
LZAGF Lonza Group Ltd

-23.59 (-4.05%)

USD 41.97B
MTD Mettler-Toledo International I..

-48.61 (-3.22%)

USD 26.69B
WAT Waters Corporation

-1.83 (-0.52%)

USD 19.21B
LH Laboratory Corporation of Amer..

+2.70 (+1.30%)

USD 17.09B
DGX Quest Diagnostics Incorporated

+2.36 (+1.70%)

USD 15.38B
RVTY Revvity Inc.

+0.75 (+0.72%)

USD 12.54B

ETFs Containing QGEN

CB1TX:SW Lyxor 1 TecDAX (DR) UCITS.. 9.41 % 0.00 %

N/A

USD 0.08B
EXS2:F iShares TecDAX UCITS ETF .. 6.69 % 0.00 %

-0.11 (0.44%)

USD 0.74B
EXS2:XETRA iShares TecDAX UCITS ETF .. 6.69 % 0.00 %

-0.06 (0.44%)

USD 0.77B
EXIB:XETRA iShares TecDAX® UCITS ET.. 6.69 % 0.00 %

-0.01 (0.44%)

USD 0.77B
E908:F Lyxor 1 - TecDAX UCITS ET.. 6.65 % 0.00 %

-0.10 (0.44%)

USD 0.08B
E908:XETRA Lyxor 1 TecDAX (DR) UCITS.. 6.65 % 0.00 %

-0.05 (0.44%)

USD 0.09B
TDXPEX:SW iShares TecDAX® UCITS ET.. 6.39 % 0.00 %

-0.02 (0.44%)

USD 5,933.97B
CF1:PA Amundi MSCI France UCITS 4.81 % 0.00 %

-0.10 (0.44%)

USD 9.14M
GN0M:XETRA Global X Genomics & Biote.. 4.07 % 0.00 %

+0.09 (+0.44%)

USD 7.05M
EKG First Trust Nasdaq Lux Di.. 4.04 % 0.00 %

+0.09 (+0.44%)

USD 2.41M
GNOG:LSE Global X Genomics & Biote.. 3.91 % 0.00 %

+0.09 (+0.44%)

USD 6.47M
CURG:LSE VanEck Genomics and Healt.. 3.56 % 0.00 %

+0.07 (+0.44%)

USD 6.86M
XMLH:XETRA L&G Healthcare Breakthrou.. 1.86 % 0.00 %

+0.13 (+0.44%)

USD 0.07B
DOCG:LSE L&G Healthcare Breakthrou.. 1.84 % 0.00 %

+10.15 (+0.44%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.84 % 0.00 %

+0.16 (+0.44%)

USD 0.07B
ZLI:CA BMO Low Volatility Intern.. 1.49 % 0.42 %

+0.12 (+0.44%)

CAD 0.34B
MVAE:PA 0.77 % 0.00 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
JPED 0.00 % 0.74 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.19 (+0.44%)

USD 0.09B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

+0.27 (+0.44%)

USD 0.06B
C007:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

-0.01 (0.44%)

USD 0.16B
E907:XETRA Lyxor 1 MDAX (DR) UCITS E.. 0.00 % 0.00 %

+0.30 (+0.44%)

USD 0.13B
ELF1:XETRA Deka MDAX® UCITS ETF 0.00 % 0.00 %

+0.75 (+0.44%)

USD 0.35B
EXS3:XETRA iShares MDAX® UCITS ETF .. 0.00 % 0.00 %

+0.45 (+0.44%)

USD 1.12B
DEAM:XETRA Invesco MDAX® UCITS ETF .. 0.00 % 0.00 %

+0.11 (+0.44%)

USD 0.24B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.98% 29% F 20% F
Dividend Return 2.95% 100% F 90% A-
Total Return -4.03% 36% F 23% F
Trailing 12 Months  
Capital Gain -9.44% 42% F 19% F
Dividend Return 2.87% 100% F 43% F
Total Return -6.57% 42% F 19% F
Trailing 5 Years  
Capital Gain 3.75% 18% F 50% F
Dividend Return 3.29% 40% F 10% F
Total Return 7.04% 18% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain 5.82% 25% F 61% D-
Dividend Return 5.99% 25% F 53% F
Total Return 0.17% 17% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 21.76% 92% A 52% F
Risk Adjusted Return 27.52% 25% F 50% F
Market Capitalization 6.46B 23% F 83% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 56.20 92% 27%
Price/Book Ratio 2.34 69% 37%
Price / Cash Flow Ratio 20.07 62% 16%
Price/Free Cash Flow Ratio 13.61 77% 29%
Management Effectiveness  
Return on Equity 9.38% 46% 56%
Return on Invested Capital 6.70% 36% 52%
Return on Assets 4.49% 46% 68%
Debt to Equity Ratio 24.21% 77% 77%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.